替格瑞洛联合瑞舒伐他汀对急性ST抬高心肌梗死患者心功能和血清学指标的影响

目的 探讨替格瑞洛联合瑞舒伐他汀对急性ST抬高心肌梗死患者心功能和血清学指标的影响。方法 选择2018年1月—2019年5月选择在宝鸡市中医医院诊治的急性ST段抬高型心肌梗死患者150例作为研究对象，根据随机数字表法将患者分为对照组和观察组，每组各75例。对照组患者在经皮冠状动脉介入治疗（PCI）术前7 d和术后口服瑞舒伐他汀钙片，10 mg/d。观察组在对照组治疗的基础上口服替格瑞洛片，90 mg/次，1次/d。两组均治疗观察3个月。比较两组患者治疗前后的6 min步行距离（6 MWT）、左室舒张末期内径（LVEDD）、左室收缩末期内经（LVESD）、左室间隔厚度（LVIVS）、左心室后壁厚度（LVPWT）、N末端脑钠肽原（NT-proBNP）和超敏C反应蛋白（hs-CRP）水平和主要心血管事件（MACE）发生情况。结果 两组治疗后的6 MWT值都显著高于治疗前（P<0.05），且观察组高于对照组（P<0.05）。两组治疗前后的LVEDD、LVESD、LVIV、LVPWT对比无统计学意义。两组治疗后的血清NT-proBNP、hs-CRP水平都显著低于治疗前（P<0.05），且观察组低于对照组（P<0.05）。观察组治疗期间的MACE发生率为5.3%，显著低于对照组的18.7%（P<0.05）。结论 替格瑞洛联合瑞舒伐他汀治疗急性ST抬高心肌梗死能抑制NT-proBNP、hs-CRP的释放，提高患者的6 MWT值，减少MACE的发生。

Effects of ticagrelor combined with rosuvastatin on cardiac function and serological indicators in patients with acute ST elevation myocardial infarction

Objective To investigate the effect of ticagrelor combined with rosuvastatin on cardiac function and serological indicators in patients with acute ST elevation myocardial infarction. Methods Patients (150 cases) with acute ST-segment elevation myocardial infarction in the Baoji Traditional Chinese Medicine Hospital from January 2018 to May 2019 were selected as study subjects. According to the random number table method, the patients were divided into control group and observation group, with 75 patients in each group. Patients in the control group were po administered with Rosuvastatin Calcium Tablets at 7 days before and after PCI, 10 mg/d. Patients in the observation group were po administered with Ticagrelor Tablets on the basis of control group, 90 mg/time, and once daily. Both groups were treated and observed for 3 months. The 6 MWT, LVEDD, LVESD, LVIVS, LVPWT, and the levels of NT-proBNP and hs-CRP in two groups before and after treatment were compared, and the occurrence of major cardiovascular events (MACE) between two groups were also compared. Results After treatment, the value of 6 MWT in two groups was significantly higher than that before treatment (P<0.05), and the observation group was higher than that in the control group (P<0.05). LVEDD, LVESD, LVIV and LVPWT in two groups before and after treatment showed no statistical significance. After treatment, the serum levels of NT-proBNP and hs-CRP in two groups were significantly lower than those before treatment (P<0.05), and the observation group was lower than those in the control group (P<0.05). During the treatment, the incidence of MACE in the observation group was 5.3%, which was significantly lower than 18.7% in the control group (P<0.05).Conclusion Ticagrelor combined with rosuvastatin in treatment of acute ST-elevation myocardial infarction can inhibit the release of NT-proBNP and hsCRP, improve the 6 MWT value of patients, and reduce the occurrence of MACE.